Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.
Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Int J Clin Pharm. 2022 Apr;44(2):557-563. doi: 10.1007/s11096-022-01379-7. Epub 2022 Feb 14.
Background In the Netherlands, home treatment with intravenous antimicrobial therapy is a relatively new concept. Although several studies have shown that outpatient parenteral antimicrobial therapy (OPAT) can be administered safely, people receiving antimicrobials at home remain at risk for adverse events, including readmission. Aim The aim of our retrospective study was to identify risk factors for readmission in patients discharged with OPAT. Method Patients who were at least 18 years or older, discharged with OPAT between January 2016-December 2018 were included. Variables that were collected consisted of baseline demographics, complications, readmission within 30 days and treatment failure. Multivariate logistic regression analysis was performed to identify risk factors for readmission. Results A total of 247 patients were included; the most common reason for OPAT was bone and joint infections (17%). Penicillin (37%), cephalosporin (26%) and vancomycin/aminoglycoside (15%) were the most commonly prescribed antimicrobials. Among patients receiving medication subject to therapeutic drug monitoring (i.e. aminoglycosides or vancomycin), 51% (19/37) received weekly therapeutic drug monitoring. Receiving aminoglycosides or vancomycin (adjusted OR 2.05; 95% CI 1.30-3.25, p < 0.05) and infection of prosthetic material (adjusted OR 2.92, 95% CI 1.11-7.65, p < 0.05) were independent risk factors associated with readmission. Conclusion Although patients receiving medication subject to therapeutic drug monitoring are at higher risk of readmission, only half of the patients discharged with aminoglycosides or vancomycin were monitored according to IDSA guidelines. A specialized team in charge of monitoring patients with OPAT is more likely to increase the rate of monitoring to prevent readmissions and complications.
背景
在荷兰,家庭静脉内抗菌治疗是一个相对较新的概念。尽管多项研究表明,门诊患者接受抗菌药物治疗(OPAT)是安全的,但在家中接受抗菌药物治疗的患者仍存在不良事件的风险,包括再次入院。
目的
本回顾性研究的目的是确定接受 OPAT 出院患者再次入院的危险因素。
方法
研究纳入 2016 年 1 月至 2018 年 12 月期间接受 OPAT 治疗的年龄至少 18 岁以上的患者。收集的变量包括基线人口统计学数据、并发症、30 天内再入院和治疗失败。采用多变量逻辑回归分析确定再入院的危险因素。
结果
共纳入 247 例患者;OPAT 的最常见原因是骨和关节感染(17%)。最常开的抗菌药物是青霉素(37%)、头孢菌素(26%)和万古霉素/氨基糖苷类(15%)。在接受治疗药物监测的药物(即氨基糖苷类或万古霉素)的患者中,51%(19/37)接受了每周治疗药物监测。接受氨基糖苷类或万古霉素(调整后的 OR 2.05;95%CI 1.30-3.25,p<0.05)和植入物感染(调整后的 OR 2.92,95%CI 1.11-7.65,p<0.05)是与再入院相关的独立危险因素。
结论
尽管接受治疗药物监测药物的患者再入院风险较高,但只有一半接受氨基糖苷类或万古霉素治疗的患者按照 IDSA 指南进行了监测。负责监测 OPAT 患者的专门团队更有可能提高监测率,以预防再入院和并发症。